Bioject Medical Technologies Inc.
HCID Member | Medical Devices & Tech
20245 SW 95th Avenue
Tualatin, OR 97062 USA
phone: 503-692-8001
fax: 503-692-6698
Symbol BJCT
Exchange Nasdaq
Founded 1985
Employees 36
www.bioject.com
Research Sector Medical Devices & Tech
Summary Description
Needle-free delivery system for the administration of therapeutic agents
Management
Ralph Makar, President & CEO Christine Farrell Vice President, Finance & Administration Richard Stout, M.D. Vice President, Clinical Affairs
Ownership
Financials


* numbers in thousands

 
Keywords
Diabetes, needle-free, injection, Pediatrics, drug delivery, insulin, vaccines, immunotherapeutics, human growth hormone, HIVAIDS, Drug Delivery

Comment | Printable Version | Aug. 27, 2008
If you work for Bioject Medical Technologies Inc. and want to update this profile, click here

Description
Bioject Medical Technologies Inc. develops and markets needle-free injection technology used to administer injectable medications.
Products / Services
Bioject's products include the Biojector 2000, Vitajet, Needle-Free Vial Adapter, and the Drug Reconstitution System.
Technology / Differentiation
Bioject's technology works by forcing liquid medication at high speeds through a tiny orifice held against the skin. This process creates an ultra-fine stream of fluid that penetrates the skin, thereby delivering medication to the patient in a fraction of a second. Bioject's needle-free injection therapy systems eliminate the risk of accidental needle stick injuries.
Market / Customers
The product is intended for healthcare professionals and home users who administer intramuscular and subcutaneous medications. According to the company, most patients that received injections with Bioject needle-free devices responded that they would prefer needle-free delivery systems for their next injections.
Status
Bioject has licensing and/or development agreements with Merck, Serono, Merial and Vical for the development of needle-free injection systems. Bioject is also conducting research to see how its delivery system can improve the efficacy of certain medications, including DNA-based vaccines and immunotherapeutics; early stage clinical testing has been promising.


2008-08-29-2389